ClearPoint Neuro Inc. Common Stock (CLPT)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I begin with the business and the numbers. ClearPoint Neuro sells a platform for minimally invasive brain procedures, including hardware and disposables. The revenue record shows progress: in fiscal 2023, revenue was $24.0M, in fiscal 2024, revenue was $31.4M, and in fiscal 2025, revenue was $37.0M. That is respectable top-line growth. But the bottom line is not there. In fiscal 2025, net income was -$25.5M, worse than -$18.9M in fiscal 2024; diluted EPS was -$0.90. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $10.9M but net income was -$11.3M, a negative 104.20% margin. The company is not earning a profit, so I cannot compute a meaningful P/E; the FairStock figure is -8.31, and the stock trades at 28.03 times book. Return on equity is -226.52% and ROCE is -24.43%. Debt-to-equity is 5.93, trailing free cash flow is -$31.3M, and FCF yield is -10.5%. The Piotroski F-Score is 1/9 and Altman Z-Score is -1.20; those are distress and weak-quality signals. The Lynch category is none, because ClearPoint has lost money in each of the last four years. A medical device platform can have switching costs and recurring disposable revenue, but the financial statements do not yet show a moat or self-sustaining economics. At $9.81 on 2026-10-13, with a $299.2M market cap, the price already assumes a lot of future success. I would want evidence of durable revenue growth, narrowing losses, and positive cash flow before calling this a sound value.

In plain English: ClearPoint Neuro makes medical equipment and disposable tools used in minimally invasive brain surgery. Revenue is growing, but the company has lost money for years and is burning cash, so the business looks financially weak today. At $9.81 per share, the price looks expensive relative to its current losses and net worth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer